AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 123815 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive physiotherapy
Number of subjects: 456
Study 123815 — intervention group
Group type: EXPERIMENTAL
Intervention: Corset
Number of subjects: 456
Study 123815 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic tablets
Number of subjects: 456
Study 30685546 — intervention group
Group type: EXPERIMENTAL
Intervention: ViSi Mobile (VM) continuous monitoring
Number of subjects: 60
Study 30685546 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthPatch (HP) continuous monitoring
Number of subjects: 60
Study 30685546 — intervention group
Group type: COMPARATOR
Intervention: Nurse measurements
Number of subjects: 60
Study 28438584 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator to improve clinician‐family communication in the ICU
Number of subjects: 28
Study 28438584 — intervention group
Group type: EXPERIMENTAL
Intervention: Training research staff to be supportive of families’ emotional needs and logistical knowledge about the ICU
Number of subjects: 28
Study 25986648 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantong Granules (high-dose, medium-dose, low-dose)
Number of subjects: 240
Study 25986648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 23906760 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye drops containing eledoisin and carnitine
Number of subjects: 40
Study 22066244 — intervention group
Group type: EXPERIMENTAL
Intervention: vitaprost plus (rectal suppositories), one suppository before going to bed 2 days before surgery and for 8 days after TUR, total course lasted for 10 days.
Number of subjects: 55
Study 22066244 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitaprost plus treatment).
Number of subjects: 55
Study 22066244 — intervention group
Group type: EXPERIMENTAL
Intervention: vitaprost plus (rectal suppositories).
Number of subjects: 55
Study 18590592 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3-enriched pork
Number of subjects: 33
Study 18590592 — intervention group
Group type: COMPARATOR
Intervention: Regular pork (control)
Number of subjects: 33
Study 16484571 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and omeprazole for Helicobacter pylori infection
Number of subjects: 0
Study 16484571 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplement (aged garlic extract and steam-distilled garlic oil)
Number of subjects: 0
Study 16484571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplement (vitamins E and C and selenium)
Number of subjects: 0
Study 16484571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15340534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV) + intravenous immunoglobulin (IVIG)
Number of subjects: 25
Study 15340534 — intervention group
Group type: COMPARATOR
Intervention: Prednisone, glucurone, luminal, Xiaoyanlidanpian (Control)
Number of subjects: 25
Study 11142413 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 7.5 mg/day
Number of subjects: 96
Study 11142413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9771366 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lignocaine with adrenaline
Number of subjects: 40
Study 9771366 — intervention group
Group type: COMPARATOR
Intervention: Control local anaesthetic solution
Number of subjects: 40
Study 7836713 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100‐micrograms bolus with a 100‐micrograms/h infusion)
Number of subjects: 20
Study 7836713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3046465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.2 mg kg‐1)
Number of subjects: 0
Study 3046465 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (0.5 mg kg‐1)
Number of subjects: 0
Study 31062119 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nut consumption during first pregnancy trimester (> 32 g/week)
Number of subjects: 2208
Study 31062119 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nut consumption during pregnancy (first trimester)
Number of subjects: 2208
Study 31062119 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nut consumption during third pregnancy trimester
Number of subjects: 2208
Study 29018896 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP extract (900 mg)
Number of subjects: 28
Study 29018896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26995368 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 3470
Study 26995368 — intervention group
Group type: COMPARATOR
Intervention: No β-blocker therapy
Number of subjects: 3470
Study 25272653 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg)
Number of subjects: 40
Study 25272653 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean (100 mg)
Number of subjects: 40
Study 25272653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg)
Number of subjects: 40
Study 25272653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg) plus Soybean (100 mg)
Number of subjects: 40
Study 22229483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay-facilitated angina management programme
Number of subjects: 142
Study 22229483 — intervention group
Group type: COMPARATOR
Intervention: Advice from an angina nurse specialist
Number of subjects: 142
Study 18701556 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every other week (eow) for 24 weeks, then switched to open-label adalimumab 40 mg eow.
Number of subjects: 311
Study 17642246 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic agents
Number of subjects: 0
Study 17642246 — intervention group
Group type: COMPARATOR
Intervention: Concomitant corticosteroids or NSAIDs
Number of subjects: 0
Study 17642246 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of biologics
Number of subjects: 0
Study 15229669 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in a warm climate (Lanzarote)
Number of subjects: 87
Study 15229669 — intervention group
Group type: COMPARATOR
Intervention: Treatment in Norway (Control)
Number of subjects: 87
Study 12395803 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2.0 mg daily
Number of subjects: 723
Study 12395803 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.2 mg daily
Number of subjects: 723
Study 12395803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study 10457878 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.2 mg kg‐1)
Number of subjects: 60
Study 10457878 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.02 mg kg‐1)
Number of subjects: 60
Study 10457878 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.05 mg kg‐1)
Number of subjects: 60
Study 10457878 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 7788574 — intervention group
Group type: COMPARATOR
Intervention: Double-blind oral challenge with food additives (monosodium glutamate, tartrazine, sulfites, erythrosine, paraoxybenzoate, sodium benzoate, lactose, aspirin, and annate) under placebo control
Number of subjects: 6
Study 7788574 — intervention group
Group type: COMPARATOR
Intervention: Exclusion diets and elimination of contactants
Number of subjects: 6
Study 7788574 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CICs)
Number of subjects: 6
Study 7788574 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein positivity
Number of subjects: 6
Study 7788574 — intervention group
Group type: COMPARATOR
Intervention: Skin-prick tests and patch tests
Number of subjects: 6
Study 1972605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (histamine H2-receptor antagonist)
Number of subjects: 7
Study 1972605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1972605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 7
Study 417376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethchlorvynol 500 mg for 14 days
Number of subjects: 4
Study 417376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethchlorvynol 500 mg
Number of subjects: 4
Study 7136838 — intervention group
Group type: EXPERIMENTAL
Intervention: Implosive, counselling and conditioning approaches
Number of subjects: 22
Study 7136838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 31122856 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 vaccine
Number of subjects: 30527
Study 31122856 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (control)
Number of subjects: 30527
Study 28651303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS) prediction
Number of subjects: 538
Study 28651303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for recurrence-free survival
Number of subjects: 538
Study 28651303 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of nomogram
Number of subjects: 538
Study 28651303 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curve
Number of subjects: 538
Study 25602633 — intervention group
Group type: EXPERIMENTAL
Intervention: Air tamponade
Number of subjects: 64
Study 25602633 — intervention group
Group type: COMPARATOR
Intervention: Gas (C 3 F 8) tamponade
Number of subjects: 64
Study 24517082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone extended release (20-100 mg every 12 hours)
Number of subjects: 510
Study 24517082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 24517082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone extended release
Number of subjects: 510
Study 23190512 — intervention group
Group type: EXPERIMENTAL
Intervention: High Hb group receiving darbepoetin alfa
Number of subjects: 321
Study 23190512 — intervention group
Group type: COMPARATOR
Intervention: Low Hb group receiving epoetin alfa
Number of subjects: 321
Study 19238909 — intervention group
Group type: EXPERIMENTAL
Intervention: Kremezin (K)
Number of subjects: 22
Study 19238909 — intervention group
Group type: COMPARATOR
Intervention: Merckmezin (M)
Number of subjects: 22
Study 17628691 — intervention group
Group type: EXPERIMENTAL
Intervention: rppTMS (repetitive paired pulse TMS)
Number of subjects: 10
Study 17628691 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS (repetitive transcranial magnetic stimulation)
Number of subjects: 10
Study 17628691 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 10
Study 14981223 — intervention group
Group type: COMPARATOR
Intervention: Weight Watchers
Number of subjects: 48
Study 14981223 — intervention group
Group type: COMPARATOR
Intervention: Individualized
Number of subjects: 48
Study 14981223 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive
Number of subjects: 48
Study 14981223 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 11844887 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine
Number of subjects: 29
Study 11844887 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine
Number of subjects: 29
Study 11844887 — intervention group
Group type: COMPARATOR
Intervention: 15 mg olanzapine
Number of subjects: 29
Study 11844887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11844887 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg or 10 mg olanzapine
Number of subjects: 29
Study 11844887 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 29
Study 10087078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye pursuit task
Number of subjects: 6
Study 10087078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-finger pursuit task
Number of subjects: 6
Study 10087078 — intervention group
Group type: COMPARATOR
Intervention: Eye fixation task
Number of subjects: 6
Study 8528469 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination of roughness
Number of subjects: 20
Study 8528469 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination of length
Number of subjects: 20
Study 8528469 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory reaction time task
Number of subjects: 20
Study 2260873 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (adreno‐oophorectomy, H)
Number of subjects: 114
Study 2260873 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (FAC, C)
Number of subjects: 114
Study 2260873 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (FAC + tamoxifen, H'C)
Number of subjects: 114
Study 2260873 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (FAC + adreno‐oophorectomy, HC)
Number of subjects: 114
Study 2260873 — intervention group
Group type: COMPARATOR
Intervention: Control group (H)
Number of subjects: 114
Study 2260873 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 114
Study 435016 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 50
Study 435016 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 50
Study 31814511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored CRC screening promotion intervention (phone counseling-only group)
Number of subjects: 603
Study 31814511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored CRC screening promotion intervention
Number of subjects: 603
Study 30242948 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.6 mg daily, titrated to 1.2 mg after the first week
Number of subjects: 62
Study 30242948 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62
Study 30242948 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 62
Study 28591244 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk beverage (150 mL for 60 days)
Number of subjects: 49
Study 28591244 — intervention group
Group type: COMPARATOR
Intervention: Non-probiotic milk (150 mL for 60 days)
Number of subjects: 49
Study 25728042 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS skills training and personalized feedback (PBS-STPF) intervention
Number of subjects: 251
Study 25728042 — intervention group
Group type: COMPARATOR
Intervention: Health-related control condition
Number of subjects: 251
Study 25728042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (PBS-STPF and control)
Number of subjects: 251
Study 25728042 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS-STPF intervention
Number of subjects: 251
Study 24084800 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual obstetric care and osteopathic manual treatment (UOBC+OMT)
Number of subjects: 144
Study 24084800 — intervention group
Group type: COMPARATOR
Intervention: Usual obstetric care and sham ultrasound therapy (UOBC+SUT)
Number of subjects: 144
Study 24084800 — intervention group
Group type: COMPARATOR
Intervention: Usual obstetric care (UOBC)
Number of subjects: 144
Study 21315807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 24
Study 21315807 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 24
Study 18851771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for psychosis (CBTp)
Number of subjects: 94
Study 18851771 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 94
Study 16778608 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL/kg of bw of a nonionic contrast agent (300 mg I/mL) injected at 4 mL/sec
Number of subjects: 130
Study 16778608 — intervention group
Group type: COMPARATOR
Intervention: 2 mL/kg of bw of a nonionic contrast agent (300 mg I/mL) injected at 3 mL/sec
Number of subjects: 130
Study 14534763 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin (2 g/kg) and aspirin (80-100 mg/kg/day) given before day 5 of illness
Number of subjects: 81
Study 14534763 — intervention group
Group type: COMPARATOR
Intervention: Immunoglobulin (2 g/kg) and aspirin (80-100 mg/kg/day) given on or after day 5 of illness
Number of subjects: 81
Study 12374709 — intervention group
Group type: EXPERIMENTAL
Intervention: TSA with 20 mL of 1.5% lidocaine (TSA-Lido)
Number of subjects: 12
Study 12374709 — intervention group
Group type: COMPARATOR
Intervention: i.v. infusion with 300 mg of lidocaine (i.v.-Lido)
Number of subjects: 12
Study 10215748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1000 mg every 8h
Number of subjects: 12
Study 10215748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimethoprim 200 mg once daily
Number of subjects: 12
Study 10215748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs concomitantly
Number of subjects: 12
Study 8642904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8642904 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.03 mg/kg)
Number of subjects: 10
Study 8642904 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (10 mg)
Number of subjects: 10
Study 2338194 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, 40 mg, twice a day
Number of subjects: 9
Study 2338194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 10 mg/kg per day
Number of subjects: 9
Study 2338194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lovastatin and ursodeoxycholic acid
Number of subjects: 9
Study 459472 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise after dehydration
Number of subjects: 20
Study 459472 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise after dehydration
Number of subjects: 20
Study 459472 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise after rehydration
Number of subjects: 20
Study 459472 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise after rehydration
Number of subjects: 20
Study 459472 — intervention group
Group type: COMPARATOR
Intervention: Control levels (predehydration)
Number of subjects: 20
Study 29959787 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat 2.5 mg
Number of subjects: 60
Study 29959787 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat 5 mg
Number of subjects: 60
Study 29959787 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg
Number of subjects: 60
Study 29959787 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat 15 mg
Number of subjects: 60
Study 29959787 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat 20 mg
Number of subjects: 60
Study 29959787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26378033 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (200 mg daily)
Number of subjects: 72
Study 26378033 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months)
Number of subjects: 72
Study 25454967 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint pressure therapy (APT)
Number of subjects: 49
Study 25454967 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral meridian therapy (CMT)
Number of subjects: 49
Study 25454967 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 49
Study 22484079 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual cues in cued recall tasks
Number of subjects: 76
Study 22484079 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual cues in recognition tasks
Number of subjects: 76
Study 22484079 — intervention group
Group type: COMPARATOR
Intervention: Cued recall
Number of subjects: 76
Study 22484079 — intervention group
Group type: COMPARATOR
Intervention: Recognition memory
Number of subjects: 76
Study 20569776 — intervention group
Group type: EXPERIMENTAL
Intervention: Unassisted bibliotherapy (n=20) with a scheduled follow‐up telephone interview, no therapist contact, treatment phase lasted for 10 weeks.
Number of subjects: 39
Study 20569776 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (n=19).
Number of subjects: 39
Study 18723851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration during head-up tilt test (HUT)
Number of subjects: 97
Study 18723851 — intervention group
Group type: COMPARATOR
Intervention: Head-up tilt test without nitroglycerin administration
Number of subjects: 97
Study 18723851 — intervention group
Group type: COMPARATOR
Intervention: Head-up tilt test before nitrate administration
Number of subjects: 97
Study 15709995 — intervention group
Group type: EXPERIMENTAL
Intervention: Beidellitic montmorillonite (3 g, t.d. for 8 weeks)
Number of subjects: 524
Study 15709995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 11799340 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 to 6.0 mg/day, median dose 2.5 mg/day)
Number of subjects: 48
Study 11799340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11799340 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 48
Study 10525747 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnitude voucher condition ($3480)
Number of subjects: 29
Study 10525747 — intervention group
Group type: COMPARATOR
Intervention: Low magnitude voucher condition ($382)
Number of subjects: 29
Study 10525747 — intervention group
Group type: COMPARATOR
Intervention: Zero magnitude voucher condition ($0)
Number of subjects: 29
Study 10525747 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (zero, low, high magnitude)
Number of subjects: 29
Study 8735684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oramorph SR (OSR)
Number of subjects: 24
Study 8735684 — intervention group
Group type: EXPERIMENTAL
Intervention: MST Continus (MST)
Number of subjects: 24
Study 8735684 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 24
Study 8735684 — intervention group
Group type: COMPARATOR
Intervention: Fed condition
Number of subjects: 24
Study 1654987 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy radiotherapy (30 fractions over 6 weeks)
Number of subjects: 474
Study 1654987 — intervention group
Group type: COMPARATOR
Intervention: 45 Gy radiotherapy (20 fractions over 4 weeks)
Number of subjects: 474
Study 1654987 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index from previous MRC study
Number of subjects: 474
Study 7065555 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11